 | |
- close
- close
|
Motley Fool
Sep 28
Comment
Some investors still think highly of these companies despite their fire-sale prices.
Bloomberg
Sep 24
Comment
(Update2) A new OxyContin formulation
designed to reduce misuse of the painkiller was recommended for
approval by outside advisers to the U.S. Food and Drug
Administration.
PR Newswire
Sep 17
Comment
CUPERTINO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) --
FierceBiotech
Jul 7
Comment
Needing time to gather data on the stability of their experimental pain med Remoxy, King Pharmaceuticals and Pain Therapeutics say they may have to wait until mid-2010 to resubmit their marketing application. The FDA snubbed the developers in...
StreetInsider.com
Jul 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/King+Pharma+%28KG%29+and+Pain+Therapeutics+%28PTIE%29+Announce+Update+on+REMOXY%28R%29+NDA/4778183.html for the full story.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
PTIE AT A GLANCE
References
| ||||||
|
|
